WuXi’s BIO 2016 Recap

WuXi News
BIO2016 Booth

Last week over 15,000 industry leaders from around the world gathered in San Francisco for the 2016 International BIO Convention to partner and learn about the latest in research, innovation, and healthcare in the biotechnology space.  At the convention, WuXi had the opportunity to connect with many of our collaborative partners, establish new relationships, participate in talks, and host a panel session and a reception.  Here’s a brief recap of some of the highlights here.

  • Dr. Richard Soll, our SVP and Head of IDSU, joined a panel of biotech entrepreneurs and biotech veterans to discuss about strategies that support breakthrough innovations.  The speakers include Kent Hawryluk, CBO of Avidity Nanomedicine, John Mulligan, Scientific Founder of Good Therapeutics, Arthur Sands, CEO of Nurix, and Christopher Denn, Partner of Goodwin Procter.  The session is moderated by Karl Handelsman, Founder of Codon Capital.  It was a dynamic conversation about the trends in platform technologies and partnerships.  “Making our capability platforms available to the pharmaceuticals and biotechs offer unique opportunities for these companies to realize their breakthrough innovations.”

rich's session at bio2016

  • Dr. Chris Chen, CEO of WuXi Biologics, discussed the emerging therapies, including drug conjugates and bispecific antibodies, and the unique manufacturing challenges these therapies present, on the session titled “Emerging Bio-Therapies and Their Manufacturing Challenges” at the 2016 BPI Theater.

Chris Chen session


  • Dr. Mu Hua, our SVP and Global Head of Product Development Service and Partnership Business Unit, took the stage with panelists Dr. Gurkeerat Singh, VP, Search and Evaluation – Emerging Markets of Eli Lilly,  Dr. Harri Jarvelainen, Partner of China Preclinical Consulting at the session “Opportunities in Drug Development and Registration in China Under Current CFDA Regulatory Reform” moderated by Marie Powers, News Editor of BioWorld Today.  Dr. Mu Hua and Dr. Gurkeerat Singh discussed about WuXi’s recent partnership with Lilly for China/global parallel drug development, strategies for advancing drugs in China, and how to work with the CFDA.

hua for wechat

  • We hosted a reception to celebrate innovation and partnerships for our collaborators, colleagues and friends as everyone gather in San Francisco for the BIO Convention.  The event drew many local and out of town professionals in biotech, pharma, research institutions, and venture capital community.  It was an exciting gathering of great minds and great fun.


Subscribe to WXPress

Receive our newsletter and information on upcoming events.